Galectin Therapeutics GALT
NASDAQ GALT
$4.61 +0.26 (+5.98%)
At close: Sep 4, 2026 · 4:00 PM EDT

Galectin Therapeutics (GALT) Debt Ratio (2024 - 2026)

Analysis

Galectin Therapeutics (GALT) Debt Ratio (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 0.05
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 0.05
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 0.12
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 0.47
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 0.26
10 Galectin Therapeutics 304.34 Mn 304.34 Mn - 2.23
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.23
Sep 30, 2025 2.53
Mar 31, 2025 2.23
Dec 31, 2024 1.21
Sep 30, 2024 0.36